Eli Lilly’s October 2024 non-exclusive evaluation agreement with Peptron remains limited to internal R&D on applying the ultrasonic spray-dried PLGA microsphere SmartDepot platform to selected peptides, with any commercial licensing explicitly optional and non-binding. The original 14-month window was extended to October 2026, yet nearly two years of joint work—including recent CNS expansions—has yielded no announced technology transfer or licensing deal despite Peptron supplying data and Lilly retaining easy termination rights. Lilly’s parallel investments in competing long-acting platforms, such as Camurus’ FluidCrystal, further reduce urgency, while the fast-approaching October 7 resolution date leaves insufficient runway for a binding commercial agreement absent a major undisclosed breakthrough. Trader consensus at 87.5% “No” reflects this structural uncertainty and the absence of recent catalysts capable of shifting the evaluation toward definitive licensing.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · Updated13% chance
$11,314 Vol.
$11,314 Vol.
Oct 6, 2026
13% chance
$11,314 Vol.
$11,314 Vol.
Oct 6, 2026
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly’s October 2024 non-exclusive evaluation agreement with Peptron remains limited to internal R&D on applying the ultrasonic spray-dried PLGA microsphere SmartDepot platform to selected peptides, with any commercial licensing explicitly optional and non-binding. The original 14-month window was extended to October 2026, yet nearly two years of joint work—including recent CNS expansions—has yielded no announced technology transfer or licensing deal despite Peptron supplying data and Lilly retaining easy termination rights. Lilly’s parallel investments in competing long-acting platforms, such as Camurus’ FluidCrystal, further reduce urgency, while the fast-approaching October 7 resolution date leaves insufficient runway for a binding commercial agreement absent a major undisclosed breakthrough. Trader consensus at 87.5% “No” reflects this structural uncertainty and the absence of recent catalysts capable of shifting the evaluation toward definitive licensing.
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Market Opened: May 5, 2026, 8:02 PM ET
Volume
$11,314End Date
Oct 7, 2026Market Opened
May 5, 2026, 8:02 PM ETResolver
0x65070BE91...This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly’s October 2024 non-exclusive evaluation agreement with Peptron remains limited to internal R&D on applying the ultrasonic spray-dried PLGA microsphere SmartDepot platform to selected peptides, with any commercial licensing explicitly optional and non-binding. The original 14-month window was extended to October 2026, yet nearly two years of joint work—including recent CNS expansions—has yielded no announced technology transfer or licensing deal despite Peptron supplying data and Lilly retaining easy termination rights. Lilly’s parallel investments in competing long-acting platforms, such as Camurus’ FluidCrystal, further reduce urgency, while the fast-approaching October 7 resolution date leaves insufficient runway for a binding commercial agreement absent a major undisclosed breakthrough. Trader consensus at 87.5% “No” reflects this structural uncertainty and the absence of recent catalysts capable of shifting the evaluation toward definitive licensing.
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Volume
$11,314End Date
Oct 7, 2026Market Opened
May 5, 2026, 8:02 PM ETResolver
0x65070BE91...Eli Lilly’s October 2024 non-exclusive evaluation agreement with Peptron remains limited to internal R&D on applying the ultrasonic spray-dried PLGA microsphere SmartDepot platform to selected peptides, with any commercial licensing explicitly optional and non-binding. The original 14-month window was extended to October 2026, yet nearly two years of joint work—including recent CNS expansions—has yielded no announced technology transfer or licensing deal despite Peptron supplying data and Lilly retaining easy termination rights. Lilly’s parallel investments in competing long-acting platforms, such as Camurus’ FluidCrystal, further reduce urgency, while the fast-approaching October 7 resolution date leaves insufficient runway for a binding commercial agreement absent a major undisclosed breakthrough. Trader consensus at 87.5% “No” reflects this structural uncertainty and the absence of recent catalysts capable of shifting the evaluation toward definitive licensing.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · Updated
Beware of external links.
Beware of external links.
Frequently Asked Questions